Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
3M Company Inc. ( MMM - Analyst Report ) is slated to release its fourth-quarter 2011 earnings result on Thursday, January 26, 2011. The current Zacks Consensus Estimate for fourth-quarter earnings per share (EPS) is $1.31, representing an annualized growth of 3.15%. For full-year 2011, the Zacks Consensus Estimate is $5.93, representing an annualized growth of 3.18%.
3M’s earnings were below the Zacks Consensus Estimate in the last quarter while the number was in line with the estimate in the second quarter of 2011. Moreover, in the first quarter of 2011 and fourth quarter 2010, earnings per share were above and in line with estimates, respectively. The company outperformed the Zacks Consensus Estimate with an average negative surprise of 0.02%.
Third Quarter Highlights
3M Company reported third-quarter 2011 earnings per share of $1.52, below the Zacks Consensus Estimate of $1.61. Earnings per share inched down 1% year over year.
Total revenue in the quarter increased by 9.6% year over year to $7.5 billion. Acquisitions contributed 3.7% to total growth, foreign exchange added 3.1%, organic volume growth 1.9% and higher year-on-year selling prices added 0.9%.
A weakness in electronic markets as well as declining growth in developed economies negatively affected organic volume in the quarter. A large number of the customers reduced their inventories due to expectations of lower demand from the customers, which affected its sales in the quarter.
Agreement of Estimate Revisions
In the last 30 days, of the analysts providing estimates on the stock, none changed their estimates for the fourth quarter or for full-year 2011 and 2012.
Magnitude of Estimate Revisions
In the last 7 days, earnings estimate for the fourth quarter decreased from $1.32 to $1.31, it dropped from $5.94 to $5.93 in 2011 and for 2012 from $6.30 to $6.29.
The company's estimate for fourth quarter, 30 days ago, was $1.32. From last 30 days, estimate for 2011 remain unchanged at $5.93 and for 2012 decreased from $6.34 to $6.29.
Our Take
The company expects to see a continued slow growth till the end of 2011, as weakening economies continues to challenge business growth. Lower demand from the customers will be mitigated by the company through fully fledged cost management and a regulated operation in developed economies. Developing markets are seen as the prime benefactors.
3M is globally recognized for its innovations, which is supported by some of its well-known brands, such as Nexcare, Post-it, Scotch, Scotch-Brite, and Scotchgard leading the market. We believe that continued capital expenditure with new product launches should bolster its prospects across most end markets.
However, the company’s growth objectives are largely dependent on timing and market acceptance of its new product offerings, including its ability to continually renew its pipeline of new offerings and bring those to the market at acceptable price points.
Further, the results have been impacted by worldwide economic and capital market conditions. Negative consumer sentiment is affecting the retail store traffic. On the corporate side, lower employment levels are negatively reducing office supply purchases in most companies.
3M Company together with its subsidiaries operates as a diversified technology company with manufacturing operations spread over 60 countries worldwide. It has more than 35 business units organized into six segments: Consumer and Office, Display and Graphics, Electro and Communications, Healthcare, Industrial and Transportation, Safety, Security and Protection Services Business. The major competitors of 3M are Avery Dennison Corporation ( AVY - Analyst Report ) , EI DuPont de Nemours & Co. ( DD - Analyst Report ) and Johnson & Johnson ( JNJ - Analyst Report ) .
We continue to maintain a Neutral rating on 3M Company for the long term and a Zacks #3 Rank (Hold recommendation) over the next one-to-three months.
Read the full Analyst Report on MMM
Read the full Analyst Report on AVY
Read the full Analyst Report on DD
Read the full Analyst Report on JNJ